Anemia and cardiovascular complications: iron and EPO impact.
Management of end-stage renal disease (ESRD) has been revolutionized by the advent of erythropoietin replacement. We briefly review its characteristics and clinical use. Also emphasized is the importance of iron deficiency in limiting the clinical response to erythropoietin therapy. Iron-replacement therapy in ESRD patients is briefly discussed.
Kurtzman
N A
NA
Texas Tech University Health Sciences Center, Department of Internal Medicine and Physiology and Combined Program in Nephrology and Renal Physiology, Lubbock, Tex. 79430, USA.
Sabatini
S
S
D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000209:etiology*; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007501:Iron / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*
D004921:Erythropoietin; D007501:Iron